Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022 > Fore Biotherapeutics Announces Fast Track Designation Granted by FDA to FORE8394 for the Treatment of Cancers Harboring BRAF Class 1 and Class 2 Alterations

Fore Biotherapeutics Announces Fast Track Designation Granted by FDA to FORE8394 for the Treatment of Cancers Harboring BRAF Class 1 and Class 2 Alterations

Fore Biotherapeutics Announces Fast Track Designation Granted by FDA to FORE8394 for the Treatment of Cancers Harboring BRAF Class 1 and Class 2 Alterations

Read also

ESMO 2025
ESMO 2025
ESMO 2025 – Merck shoots for an ovarian cancer first
Clarametyx
Clarametyx
Clarametyx completes enrolment in cystic fibrosis trial
Pelage Pharmaceuticals’ alopecia
Pelage Pharmaceuticals’ alopecia
Pelage Pharmaceuticals’ alopecia treatment moves forward to phase 3 trial
J&J’s Tecvayli-Darzalex
J&J’s Tecvayli-Darzalex
J&J’s Tecvayli-Darzalex  trumps SoC in multiple myeloma
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand